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Abstract
Background:Pulse oximetry screening is a highly accurate tool for the early detection of critical congenital heart disease (CCHD) in
newborn infants. As the technique is simple, noninvasive, and inexpensive, it has potentially significant benefits for developing
countries. The aim of this study is to provide information for future clinical and health policy decisions by assessing the cost-
effectiveness of CCHD screening in China.
Methods and Findings: We developed a cohort model to evaluate the cost-effectiveness of screening all Chinese newborns
annually using 3 possible screening options compared to no intervention: pulse oximetry alone, clinical assessment alone, and pulse
oximetry as an adjunct to clinical assessment. We calculated the incremental cost per averted disability-adjusted life years (DALYs) in
2015 international dollars to measure cost-effectiveness. One-way sensitivity analysis and multivariate probabilistic sensitivity
analysis were performed to test the robustness of the model. Of the three screening options, we found that clinical assessment is the
most cost-effective strategy compared to no intervention with an incremental cost-effectiveness ratio (ICER) of Int$5,728/DALY,
while pulse oximetry plus clinical assessment with the highest ICER yielded the best health outcomes. Sensitivity analysis showed
that when the treatment rate increased up to 57.5%, pulse oximetry plus clinical assessment showed the best expected values
among the three screening options.
Conclusion: In China, for neonatal screening for CCHD at the national level, clinical assessment was a very cost-effective
preliminary choice and pulse oximetry plus clinical assessment was worth considering for the long term. Improvement in accessibility
to treatment is crucial to expand the potential health benefits of screening.
Abbreviations: ACER = average cost-effectiveness ratio, CCHD = critical congenital heart disease, CHD = congenital heart
disease, DALYs = disability adjusted life years, GDP = gross domestic product, ICER = incremental cost-effectiveness analysis,
WHO = World Health Organization, WTP = willingness-to-pay.
Keywords: China, critical congenital heart disease, economic evaluation, neonatal screening, pulse oximetry
1. Introduction
Congenital heart defects (CHD) are the most common type of
birth defect and a leading cause of infant mortality in China
where approximately 216,000 infants with CHD are born every
year [1]. The worldwide prevalence of CHD is estimated at 4 to
10 per 1000 neonates; of these, 1 to 2 neonates have critical CHD
(CCHD), which can cause death or the need for surgical or
catheter-based intervention in the neonatal period.[2] Population-
based studies in Europe and America have shown the accuracy
and value of adding pulse oximetry screening to the routine
clinical assessment of neonates to aid in the detection of
CCHD.[3–6] Early detection is critical to preventing infant
morbidity and mortality. Combined with advances in therapeutic
interventions, early detection can enable the majority of children
born with CCHD to lead normal productive lives.[7]
In 2011, after being widely advocated by major medical
societies, pulse oximetry screening of newborns for CCHD was
included in the US-recommended uniform screening panel.[2,7,8]
CCHD screening reportedly reduced the number of apparently
healthy infants who might have died or suffered cardiovascular
collapse without CCHD detection.[9–11] The impact of screening
for CCHD in developing countries, however, is less certain.
Owing to delays in timely diagnosis and case management, infant
and child mortality related to CCHD remains high in developing
countries.[12] As pulse oximetry screening provides an accurate,
noninvasive approach that is simple, inexpensive, and less
resource-intensive, it could be very beneficial for developing
countries as long as access to treatment is available after
detection.
A large-scale, multicenter, prospective screening study con-
ducted in China confirmed the feasibility and accuracy of pulse
oximetry screening for the detection of CCHD in neonates before
discharge and recommended its widespread use in maternity
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hospitals.[13] This screening method is considered feasible for the
majority of Chinese neonates because the pulse oximeter is
readily available in most secondary and tertiary hospitals,
screening can also be provided by outreach services, and the
proportion of neonates delivered at hospitals exceeds 90%.
However, there are tremendous variations in socioeconomic
status, access to antenatal screening and pediatric cardiological
care, and performance and quality of healthcare across regions
and facilities. Neonatal screening for CCHD is still at the pilot
stage and has not yet been widely adopted in most Chinese
hospitals. No study has yet evaluated the cost-effectiveness of
CCHD screening in a developing country. Therefore, this study
aimed to evaluate the cost-effectiveness of neonatal CCHD
screening for neonates in China.
2. Methods
2.1. Decision model
A decision-analytic and cost-effectiveness analysis model was
generated using TreeAge Pro.2015 (Fig. 1) and was programmed
for a hypothetical annual birth cohort of 16million neonates. The
aim of the screening was to detect neonates with CCHD, whose
condition had gone undiagnosed during antenatal care, before
they were discharged from the birth hospital so that timely
treatment could be administered before cardiac collapse. The
primary outcomes were the number of lives saved during infancy
and the Disability-Adjusted Life Years (DALYs) averted as a
result. The time horizon was the lifetime.
Three screeningoptions, namely, clinical assessment alone,pulse
oximetry screening alone, and pulse oximetry screening as an
adjunct to clinical assessment for early detection of CCHD, were
compared to no intervention (status quo). Clinical assessment has
always been fundamental to routine clinical practice in China
where it encompasses 4 components: family history, particular
facial features, heart murmurs, and extra cardiac malformation
and is carried out before discharge (depending on the human and
technical capacities of the hospital).[13] Because neither clinical
assessment nor pulse oximetry alone can detect all CCHD, a
combination of the 2 is ideal.[14]
Infants in whom CCHD was diagnosed by fetal ultrasound
during antenatal care were excluded from postnatal screening.
Pulse oximetry measures the oxygen saturation of arterial blood
24 to 48hours after birth. Whenever a positive result was
identified by screening, the neonate underwent a diagnostic
echocardiogram at the birth hospital or was referred to another
hospital as needed. Furthermore, neonates with a CCHD
diagnosis were expected to receive pediatric cardiological care
including surgery or catheterization generally at the tertiary level
before cardiovascular collapse.
2.2. Costs
Cost estimates were based on the societal perspective and
discounted at 3%.[15] Data were first collected in Chinese yuan in
2015 and then converted to international dollars using purchas-
ing power parities and gross domestic product (GDP) defla-
tors.[16] The estimates included 3 items: cost of screening by either
clinical assessment or pulse oximetry, the cost of diagnostic
echocardiography, and the cost of treatment.
The cost of pulse oximetry screening was estimated based on
the salaries of doctors and nurses and the average screening time,
reported as 1.6 minutes.[13] We also considered equipment and
maintenance costs and program costs for implementing screen-
ing. The figures for the salary of the medical staff and the direct
medical costs for clinical assessment, echocardiography tests,
surgery, and catheterization were obtained from tertiary
hospitals and local health services, as infants with, or suspected
of having, CCHD in rural areas are referred to tertiary hospitals
in urban centers for diagnosis and treatment (pediatric cardiac
surgery or catheterization). Considering the diversity in the cost
of screening and diagnosis across health facilities at different
levels, an up-and-down level of 50% was used in the sensitivity
analysis to examine these uncertainties (Table 1).
Figure 1. Decision model.
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2.3. Screening performance and diagnostic follow-up
Data on screening accuracy were obtained from the largest
multifacility investigation in the developing world, which was
conducted by Zhao et al.[13] As screening performance was likely
to vary across different health facility levels, sensitivity and
specificity were reduced by 50% in the sensitivity analysis, taking
into account the probability that lower level and remote hospitals
would perform more poorly than major urban hospitals.
Generally, newborns can receive a diagnostic echocardiogram
either at the birth hospital or a nearby tertiary hospital, and
confirmed cases receive pediatric cardiological care at a tertiary
hospital. Table 2 shows the base-case values and plausible ranges
used for the sensitivity analysis.
2.4. Estimates of health impacts
The model assessed the number of additional neonates with
CCHD detected at the birth hospital before discharge, the
number of lives saved, and the number of disability adjusted life
years (DALYs) averted. The willingness-to-pay (WTP) threshold
was calculated at 34,857 international dollars (Int$) per DALY
averted, or 3 times the GDP per capita based on the WHO
guidelines for cost-effectiveness analysis of interventions.[16]
In China, access to healthcare, especially advanced-level
pediatric cardiological care, varies widely across the country.
Unlike in developed countries, a significant proportion of infants
with CCHD are unable to receive any treatment before
cardiovascular collapse. Given the lack of data on infant mortality
without treatment, the adverse outcomes owing to poor access to
pediatric cardiological care were estimated by using a proxy of the
natural history derived from a study conducted in the 1950s when
cardiac surgery was not commonly available worldwide. We also
used recent reports on infant mortality oowing to CCHD in China
to reflect health outcomes with treatment, under the assumption
that the probability of death would be reduced if CCHD was
detected before discharge and the neonate received advanced-level
pediatric cardiological care. The average and incremental costs per
DALYs averted were calculated.
2.5. Sensitivity analysis
For the base-case, univariate sensitivity analyses were conducted
to explore the impact of the parameters listed in Table 2 on the
cost, health outcomes, and cost-effectiveness of the 3 screening
options. Monte Carlo simulations were then applied to the
multivariate sensitivity analyses to test the robustness of the
model while taking into account simultaneous changes in key
parameters whose variations had the greatest impact on cost-
effectiveness.
2.6. Ethical consideration
As our study was a modeling-based approach and data for cost
estimates did not include individual information, no ethical
approval was necessary.
Table 1








Clinical assessment 0.5 0.2–0.8
Pulse oximetry 2 1–3
Diagnosis 35.0 30–40
Pediatric cardiological care 31,098 95% CI: 25,912–42,064
CHD=congenital heart disease.
Table 2




Annual birth cohort of newborns 16,000,000 (—) [22]
Life expectancy in Chinese population 75 (—) [22]
Prevalence of CHD 0.8% 0.6%–1.3% [1,23–25]
Prevalence of critical CHD 0.2% 0.1%–0.3% [1,23–25]
Sensitivity of pulse oximetry for CHD 58.7% 53.2%–64.0% [13]
Sensitivity of clinical assessment for CHD 81.3% 76.6%–85.2% [13]
Sensitivity of pulse oximetry plus clinical assessment for CHD 90.2% 86.4%–93.0% [13]
Sensitivity of pulse oximetry for critical CHD 83.6% 76.7%–88.7% [13]
Sensitivity of clinical assessment for critical CHD 77.4% 70.0%–83.4% [13]
Sensitivity of pulse oximetry plus clinical assessment for critical CHD 93.2% 87.9%–96.2% [13]
Specificity of pulse oximetry for CHD 99.7% 99.7%–99.8% [13]
Specificity of clinical assessment for CHD 97.4% 97.3%–97.5% [13]
Specificity of pulse oximetry plus clinical assessment for CHD 97.3% 97.2%–97.4% [13]
Specificity of pulse oximetry for critical CHD 99.7% 99.6%–99.7% [13]
Specificity of clinical assessment for critical CHD 97.3% 97.2%–97.4% [13]
Specificity of pulse oximetry plus clinical assessment for critical CHD 97.1% 97.1%–97.2% [13]
Neonatal screening coverage 90% 80%–100% Expert’s opinion based on
facility-based delivery
from the 5th National
Health Service Survey[26]
Proportion of infants with critical CHD access to pediatric cardiological care 30% 10%–50% Expert opinion
Infant mortality due to critical CHD (without treatment) 75% 60%–90% [27,28]
Infant mortality due to critical CHD (with treatment) 25% 20%–30% [29,30]
Discounting rate 3% 1.5%–6% [16]
CHD=congenital heart disease.




Table 3 showed the expected values and cost-effectiveness of the
3 options. Of the 3 screening strategies, clinical assessment alone
was very cost-effective, with an incremental cost-effectiveness
ratio (ICER) of Int$7528/DALY averted from no intervention
(95% CI: 5322–11,604). Pulse oximetry screening alone was
dominated. As for the combined strategy, the average cost-
effectiveness ratio (ACER) pulse oximetry as an adjunct to
clinical assessment is under the threshold of WTP, Int$34,857/
DALY, whereas its ICER compared to clinical assessment alone
was Int$56,778/DALY averted (95% CI: 48,020–65,482)
(Fig. 2).
3.2. Sensitivity analysis
The results of the 1-way sensitivity analysis by parameter for
the cost-effectiveness of the 3 screening options are shown in a
Tornado diagram (Fig. 3). The parameter with the greatest range
was the proportion of patients receiving pediatric cardiological
care, followed by infant mortality averted by timely treatment,
unit cost of pulse oximetry screening, the prevalence of CCHD,
and the proportion of suspected cases, which were diagnosed.
Because treatment rate was found to be the most influential
parameter and equal in importance to the proportion of patients
receiving pediatric cardiological care, its impact on cost-
effectiveness and the expected value of different screening
options was explored, as shown in Figure 4. When the treatment
rate was increased to 57.5%, the ICER of pulse oximetry plus
clinical assessment acquired the best expected values among the
3 options at the threshold of Int$34,857/DALY.
The cost-effectiveness acceptability curve indicated the robust-
ness of the cost-effectiveness of different options at different
WTP thresholds. At a threshold of Int$34,857/DALY, clinical
assessment alone was very cost-effective with a probability of
100%. The probability of cost-effectiveness of pulse oximetry
plus clinical assessment gradually increased with the WTP
threshold and exceeded that of clinical assessment when the
threshold reached Int$57,000/DALY (Fig. 5).
4. Discussion
To the best of our knowledge, this study provides the first cost-
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Figure 2. Cost-effectiveness of screening options.
Figure 3. Tornado diagram (1 sensitivity analysis of ICER of the combined strategy vs. clinical assessment alone).
Table 3
Estimates of expected values of costs and health impacts.
Screening strategies Estimated costs, Int$ (95% CI) DALYs averted (95% CI) ICER (95% CI)
No intervention 0 0 (—)
Clinical assessment 2,798,053 (2,775,895–2,814,737) 371.67 (242.56–521.57) 7,528 (5322–11,604)
Pulse oximetry 3,172,834 (3,162,109–3,184,932) 322.65 (213.48–487.43) Dominated
Pulse oximetry plus clinical assessment 5,918,728 (5,887,615–5,938,153) 426.63 (256.18–576.15) 56,778 (48,020–65,482)
CI= confidence interval, DALYs=disability adjusted life years, ICER= incremental cost-effectiveness analysis.
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screening in maternity hospitals in China as well as in the
developing world. Screening makes it possible to detect CCHD
before discharge, potentially reducing infant deaths because of
late case management. Our analysis found that under base-case
assumptions, clinical assessment was a very cost-effective
preliminary choice. Pulse oximetry plus clinical assessment,
however, yielded the best health outcomes onDALYs averted and
became the dominant option as the WTP threshold and the
proportion of patients receiving pediatric cardiological care
increased.
Clinical assessment is a basic practice for detecting CCHD and
can be implemented immediately after delivery. It is not yet a
routine practice in China owing to varying human and technical
capacities across regions and institutions. Training is necessary
for physicians at lower level and remote hospitals to recognize
typical symptoms such as heart murmurs, tachypnea, and overt
cyanosis. Compared with pulse oximetry, clinical assessment
demonstrated a higher detection rate for critical left heart
syndrome, critical coarctation of the aorta, interrupted aortic
arch, and critical aortic stenosis, whereas pulse oximetry was
more likely to detect total anomalous pulmonary venous
connection, transposition of the great arteries, pulmonary atresia,
and double outlet right ventricle.[13] Therefore, the combination
of pulse oximetry with clinical assessment is likely to improve
performance significantly and is an ideal option for achieving the
best screening results. Once the treatment rate, that is, the
proportion of children with CCHD who are able to access
pediatric cardiological care increases to 57.5%, this combined
approach will become cost-effective and practicable for use in
hospitals universally in the long term.
The findings of our study highlighted the impact of accessibility
to pediatric cardiological care on the health and economic effects
of screening strategies. It is reasonable to predict that the timely
treatment of infants with positive screening results for CCHD
will improve significantly if screening were to be universally
introduced. However, in light of China’s low “ceiling” levels,
post-payments, and various restrictions on reimbursements, the
current medical insurance system is failing to fulfill its protective
function against catastrophic payments and impoverishment
owing to serious illness including CHDs, particularly for rural
and rural-to-urban migrant children. Medical expenditures for
pediatric cardiological care principally relies on out-of-pocket
payments and charities, with an actual reimbursement rate of
20% to 45% or even <20% for payments exceeding 200,000
Figure 4. Impact of treatment rate on cost-effectiveness and expected value of different screening options.
Figure 5. Acceptability curve.
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Chinese yuan, a figure far removed from the Ministry of Health’s
ambitious target of 90%.[17] Questions also remain regarding the
highly concentrated distribution of advanced medical technology
for diagnosis and treatment in urban hospitals. This situation
leads to difficulties not only in access but also reimbursement
because healthcare obtained outside of one’s area of residence is
subject to much lower reimbursement and complicated proce-
dures. Furthermore, significant geographical gaps remain in
facilities’ technical capacity for pediatric cardiological care across
the country. Timely treatment after early detection is often
hindered by catastrophic payments because of out-of-pocket
expenses and the lack of advanced medical technology in lower
level and remote facilities, which negatively affect the potential
benefits of screening strategies, especially those of pulse oximetry
as an adjunct to clinical assessment.
Previous economic evaluations of neonatal CCHD screening
have been published, but all were conducted in the developed
world.[18–21] Although these studies suggested that screening by
pulse oximetry plus clinical assessment was cost-effective in light
of the accepted thresholds in high-income countries, in China and
other developing countries, the health system and socioeconomic
environment influencing clinical and policy decision-making
differ from those of developed countries. First, access to pediatric
cardiological care is limited by technical, geographical, and
financial factors, whereas an access rate >10% was reported
for the developing world.[12] Second, China has huge gaps in
socioeconomic status as well as in the quality, capacity, and
accessibility of medical care. Last but most importantly, the WTP
threshold varies significantly across regions in China, causing
correspondingly greater variations in cost-effectiveness analysis
results than in developed countries.
This study has some limitations. A major limitation is the lack
of precise population-based information on the outcomes of
childhoodmortality andmorbidities during the long term in cases
of timely treatment, delayed treatment, and no treatment, and the
impact of early detection by neonatal or prenatal screening on the
improvement of those outcomes. We primarily considered
DALYs because of infant mortality averted based on currently
available information. However, the potential health benefits are
not limited to infant mortality, but also include morbidities
avoided in the long term and facilitating and informing pediatric
cardiological care. Additionally, we did not investigate the impact
of secondary life-threatening neonatal conditions that may be
detected by pulse oximetry, such as pneumonia and sepsis. In the
developing world, the detection of these conditions may be of
more benefit than the detection of CCHD. Therefore, the
potential benefits of neonatal CCHD screening may be largely
underestimated. Moreover, data on screening performance
derived from urban tertiary hospitals and real-world accuracy
in lower-level hospitals are likely to be poorer and largely
dependent on physicians’ clinical experience and facility capacity.
To adjust for this uncertainty, we reduced sensitivity by 50% in
the sensitivity analysis. Finally, owing to the lack of information,
the proportion of infants with CCHD receiving pediatric
cardiological care was based on the opinion of an expert panel.
To adjust for this uncertainty, we set a wide range in the
sensitivity analysis to accommodate the huge geographical and
socioeconomic diversity within the country.
5. Conclusion
In China, for neonatal screening of CCHD at the national level,
clinical assessment is a very cost-effective preliminary choice and
pulse oximetry plus clinical assessment is worth considering for
the long term as accessibility to timely treatment improves and
the WTP threshold increases with socioeconomic development.
Public investment and insurance coverage for children with
CCHD are crucial for exploiting the health benefits of the
screening.
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